SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is a battleground after mixed earnings revealing robust subscriber and revenue growth collided with declining gross margins and escalating legal challenges concerning its compounded GLP-1s, intensifying a tug-of-war between bulls and bears amid high short interest.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is trending due to a major strategic collaboration with Astellas to advance its PSMA-targeted PRO-XTEN T-cell engager, VIR-5500, bolstered by encouraging updated Phase 1 data demonstrating anti-tumor activity and a favorable safety profile in prostate cancer. This substantial deal is fueling community excitement and discussions about its potential to drive a short squeeze and re-rate the stock, though some investors remain cautious about historical volatility.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is seeing intense discussion and a significant sell-off as fears escalate that AI, particularly Anthropic's Claude, will fundamentally disrupt and devalue established software businesses; however, a vocal part of the community dismisses this as exaggerated market manipulation and an irrational overreaction.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending due to a significant stock drop, fueled by fears that Anthropic's Claude Code could disrupt its COBOL modernization and legacy consulting services. The community is debating if this is an overreaction or a legitimate AI-driven threat to Big Blue's established business model, despite IBM's existing AI initiatives and partnerships.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide Inc. is trending following its robust Q3 earnings, showcasing a staggering 761% year-over-year robotaxi revenue growth and improved gross margins, fueling confidence in its path to profitability. The immediate catalysts include the launch of fully driverless commercial robotaxi services with Uber in Abu Dhabi and the award-winning performance of its WePilot ADAS system gaining OEM traction, even as the community expresses frustration over the stock's valuation disconnect despite significant institutional interest from ARK Invest.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos is seeing strong conversation after a solid Q4 earnings report, a new GE Aerospace engine contract for combat drones, and its selection for the $1.1 billion Drone Dominance Program. The community is largely bullish on the company's expansive pipeline in autonomous and hypersonic defense systems, viewing it as a pivotal player in the evolving global security landscape.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as its upcoming Q4 earnings report is seen as a critical 'make-or-break' moment for validating its long-term 1,000+ qubit roadmap and commercial strategy. The community remains sharply divided between those optimistic about its strategic initiatives and those concerned with current valuation, R&D execution, and insider selling within the highly speculative quantum sector.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is trending following a strong Q4 earnings beat driven by global comparable sales growth and ambitious plans to expand to 50,000 restaurants by 2027, with the community actively debating if its defensive characteristics and value strategy can sustain momentum amid broader consumer spending concerns and competitor struggles.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU Crypto is trending due to its highly active community consistently building a "permissionless brand" through various real-world product initiatives and events. Community members are actively discussing its long-term potential, encouraging accumulation during market dips, and highlighting its resilience and continuous development in challenging market conditions.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is trending amidst an immediate leadership change as its co-founder steps back into the CEO role to steer the company's AI transformation, intensifying community discussion on the software sector's resilience against AI disruption following its latest earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Achieve Life Sciences (NASDAQ:ACHV) Stock Crosses Above 200 Day Moving Average - What's Next?

Achieve Life Sciences (NASDAQ:ACHV) Shares Pass Above Two Hundred Day Moving Average - Here's What Happened...

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five analysts that are presently covering the company...

Achieve Life Sciences (NASDAQ:ACHV) Stock Price Crosses Above 200-Day Moving Average - Here's Why

Achieve Life Sciences (NASDAQ:ACHV) Stock Crosses Above Two Hundred Day Moving Average - What's Next...

What is HC Wainwright's Forecast for ACHV FY2030 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - HC Wainwright issued their FY2030 EPS estimates for shares of Achieve Life Sciences in a note issued to investors on Monday, January 26th. HC...

Achieve Life Sciences (NASDAQ:ACHV) Stock Passes Above Two Hundred Day Moving Average - Here's What Happened

Achieve Life Sciences (NASDAQ:ACHV) Shares Pass Above Two Hundred Day Moving Average - Time to Sell...

Achieve Life Sciences Promotes Mark Rubinstein As Chief Medical Officer

(RTTNews) - Achieve Life Sciences, Inc. (ACHV), a late-stage specialty pharmaceutical company, said Monday it has confirmed the promotion of Mark Rubinstein from Interim Chief Medical Officer to...

Achieve Life Sciences (NASDAQ:ACHV) Share Price Crosses Above 200-Day Moving Average - Here's Why

Achieve Life Sciences (NASDAQ:ACHV) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell...

<p>Hunterbrook Capital on Tuesday revealed it is long on Achieve Life Sciences (ACHV) stock as the company nears a green light from the U.S. Food and Drug Administration for Cytisinicline as a treatment for smoking addiction.</p><p>The FDA is expected to rule on Achieve Life Sciences’ application seeking approval for the drug by June 20, 2026. If approved, the company plans to sell it in the U.S. by the end of the year.</p><p>Hunterbrook Media <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://hntrbrk.com/achieve/">said</a> that Cytisinicline is already used in Europe and added that smoking cessation clinicians, scientists, and health program directors that it interviewed recommended approval in the U.S.</p><p>The report also noted that Cytisinicline has proven safer and more effective than its predecessors including Pfizer’s Chantix and GlaxoSmithKline’s Zyban. Chantix, despite side effects, earned over $1 billion in peak annual sales and it, like GSK’s Zyban, also required longer treatment than Cytisinicline, the firm said.</p><p>Furthermore, despite smoking being on the decline, it is still rampant, the firm noted.</p><p>There are about 29 million American cigarette smokers and about 28 million e-cigarette users, including many middle and high schoolers, the firm said. While about a half of this population try to quit, only a small portion succeeds.</p><h2 class="st-heading-2">FDA Priority Review Voucher</h2><p>The FDA awarded Achieve a Commissioner's National Priority Voucher (CNPV) aimed at expediting review for Cytisinicline in October. “It's been nearly two decades since a new treatment option for smoking cessation was approved, and there are currently no treatment options for vaping cessation,” Achieve CEO Rick Stewart said then.</p><h2 class="st-heading-2">Hunterbrook Flags Potential Headwinds</h2><p>“As with all applications, the FDA could still require additional data or studies if any safety concerns arise. Achieve also needs to maintain long-term access to cytisinicline supply. &nbsp;The company is in a legal dispute with its original supplier, Sopharma, though Achieve named other suppliers in its FDA application,” Hunterbrook said.</p><p>The firm also flagged funding concerns, highlighting that while Achieve is funded through the second quarter of 2026, it will need to raise more capital to commercialize the drug after receiving approval.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>ACHV stock traded 7% higher at the time of writing. On Stocktwits, retail sentiment around ACHV jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to 'normal' levels.</p><p><a href="https://stocktwits.com/symbol/ACHV">ACHV stock</a> has gained 34% this year and by about 31% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/walmart-app-website-down-for-users-amid-new-year-shopping-rush/cL7I4vlREyI">Walmart App And Website Down For Users Amid New Year Shopping Rush</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, the Achieve Life Sciences logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Achieve Life Sciences’ Smoking Treatment Likely To Be Approved By FDA, Says Hunterbrook

The FDA is expected to rule on Achieve Life Sciences’ application seeking approval for the drug by June 20, 2026.

Equity

Achieve Life Sciences (NASDAQ:ACHV) Shares Cross Above Two Hundred Day Moving Average - Here's Why

Achieve Life Sciences (NASDAQ:ACHV) Stock Passes Above Two Hundred Day Moving Average - What's Next...

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Average Rating of "Moderate Buy" by Analysts

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five brokerages that are covering the stock, MarketBeat Ratings reports...

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

ACHV
Achieve Life Sciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACHV News

ACHVAchieve Life Sciences Inc.